Considering the controversial role of CRABP2 in different tumors, our previous pan-cancer analysis supported an association between high CRABP2 expression and adverse outcomes in breast, lung, and ovarian cancers, and the high level of CRABP2 promotes docetaxel resistance in breast cancer [31]. The gene discussed is CRABP2; the disease is ovarian cancer.